Drug intelligence / Profile preview

SteMos1

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SteMos1 (VRC-FLUMOS0122-00-VP) is an investigational quadrivalent universal influenza vaccine candidate developed by the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. The vaccine utilizes a self-assembling ferritin nanoparticle platform to display the highly conserved hemagglutinin (HA) stem region antigens. Unlike traditional seasonal vaccines that target the rapidly mutating HA head domain, SteMos1 is designed to elicit broad-spectrum, long-lasting immunity against a wide range of seasonal and potential pandemic influenza strains. It is currently being evaluated in a Phase 1 clinical trial (VRC 329) to assess safety and immunogenicity, both as a standalone formulation and when administered with the ALFQ (Army Liposome Formulation containing saponin QS-21) adjuvant.

Other names: VRC-FLUMOS0122-00-VPVRC-FLUMOS-0122-00-VPVRC-FLUMOS 0122-00-VPquadrivalent influenza HA stem vaccine

Targets

Group 1 HA stalk (Influenza A hemagglutinin stalk domain, group 1)

Beyond the preview

Go deeper on SteMos1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SteMos1.

Explore the full profile